{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000137","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.251478+00:00","generated_at":"2026-06-14T00:23:19.129963+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera","bullets":["Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.","Pays $30M upfront, milestone payment, and low single-digit royalty on Greater China net sales of azenosertib, ZN-d5, ZN-c5.","Sold its 40.3% equity stake in Zentera back to Zentera for de minimis consideration."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000137","json":"https://secwatch.observer/filing/0001725160-23-000137.json","markdown":"https://secwatch.observer/filing/0001725160-23-000137.md","text":"https://secwatch.observer/filing/0001725160-23-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/0001725160-23-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/zntl-20230615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:23:19.129963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}